Bicara Therapeutics is headquartered at 116 Huntington Avenue, Suite 703, Boston, MA 02116.
Bicara Therapeutics was incorporated in December 2018 in Delaware.
Bicara Therapeutics’ stock is traded on the NASDAQ Global Market under the ticker symbol “BCAX”.
Bicara Therapeutics’ fiscal year-end is December 31st.
Bicara Therapeutics’ transfer agent is:
Computershare Trust Company, N.A.
web.queries@computershare.com
1-800-736-3001, option 1 (U.S.)
1-781-575-3100, option 1 (non-U.S.)
Bicara Therapeutics’ legal counsel is Goodwin Procter LLP. The company’s independent auditor is KPMG.
Corporate news can be found in the News & Events section of our Investors webpage. Quarterly and annual reports, as well as other SEC filings, can be found in the Financials section of our Investors webpage or directly from the SEC at www.sec.gov.
The Company’s financial documents can be found in the Financials section of our Investors webpage or directly from the SEC at www.sec.gov.
The date and location of Bicara’s next annual meeting will be communicated prior to the meeting date.
Please email ir@bicara.com.
Alerts can be set up from the “Email Alerts” section of the “Investors” page.
Our current analyst coverage can be found in the Stock Information section of our Investors webpage.
Shares can be purchased through a stockbroker of your choice.
Bicara does not currently have a direct stock purchase plan.